The American Journal of Medicine
Volume 119, Issue 3 , Pages 255-266 , March 2006

Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study

  • Gurkirpal Singh, MD

      Affiliations

    • Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Calif
    • Corresponding Author InformationRequests for reprints should be addressed to Gurkirpal Singh, MD, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Institute of Clinical Outcomes Research and Education (ICORE), 100 Hamilton Avenue, Suite 225 #22, Palo Alto, CA 94301
    • ,
  • John G. Fort, MD

      Affiliations

    • Pfizer, Inc., Peapack, NJ
    • ,
  • Jay L. Goldstein, MD

      Affiliations

    • Department of Medicine, University of Illinois at Chicago
    • ,
  • Roger A. Levy, MD

      Affiliations

    • Universidade do Estado do Rio de Janeiro, Brazil
    • ,
  • Patrick S. Hanrahan, MD

      Affiliations

    • Sir Charles Gairdner Hospital, Hornsby, Western Australia
    • ,
  • Alfonso E. Bello, MD

      Affiliations

    • Department of Medicine, University of Illinois at Chicago
    • ,
  • Lilia Andrade-Ortega, MD

      Affiliations

    • Rheumatology Department, Centro Medico Nacional 20 de Noviembre ISSSTE, Mexico, Mexico
    • ,
  • Carl Wallemark

      Affiliations

    • Pfizer, Inc., Peapack, NJ
    • ,
  • Naurang M. Agrawal, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • ,
  • Glenn M. Eisen, MD

      Affiliations

    • Department of Medicine, Oregon Health and Sciences University, Portland
    • ,
  • William F. Stenson, MD

      Affiliations

    • Department of Medicine, Washington University Medical School, St. Louis, Mo
    • ,
  • George Triadafilopoulos, MD

      Affiliations

    • Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Calif
    • ,
  • SUCCESS-I Investigators

References 

  1. Wolfe MM , Lichtenstein DR , Singh G . Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs . N Engl J Med . 1999;340:1888–1899
  2. Singh G , Triadafilopoulos G . Epidemiology of NSAID-induced GI complications . J Rheumatol . 1999;26(suppl):18–24
  3. Deeks JJ , Smith LA , Bradley MD . Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis (systematic review of randomised controlled trials) . BMJ . 2002;325:619–626
  4. Ekman EF , Fiechtner JJ , Levy S , Fort JG . Efficacy of celecoxib versus ibuprofen in the treatment of acute pain (a multicenter, double-blind, randomized controlled trial in acute ankle sprain) . Am J Orthop . 2002;31:445–451
  5. Saag K , van der Heijde D , Fisher C , et al.  Osteoarthritis Studies Group   Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs (a 6-week and a 1-year trial in patients with osteoarthritis) . Arch Fam Med . 2000;9:1124–1134
  6. Geusens PP , Truitt K , Sfikakis P , et al.   A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis . Scand J Rheumatol . 2002;31:230–238
  7. Morrison BW , Christensen S , Yuan W , et al.   Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain (a randomized, controlled trial) . Clin Ther . 1999;21:943–953
  8. Goldstein JL , Silverstein FE , Agrawal NM , et al.   Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor . Am J Gastroenterol . 2000;95:1681–1690
  9. Langman MJ , Jensen DM , Watson DJ , et al.   Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs . JAMA . 1999;282:1929–1933
  10. Silverstein FE , Faich G , Goldstein JL , et al.   Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study . JAMA . 2000;284:1247–1255
  11. Bombardier C , Laine L , Reicin A , et al.  VIGOR Study Group   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis . N Engl J Med . 2000;343:1520–1528
  12. Schnitzer TJ , Burmester GR , Mysler E , et al.   Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications (randomised controlled trial) . Lancet . 2004;364:665–674
  13. Hochberg MC , Chang RW , Dwosh I , Lindsey S , Pincus T , Wolfe F . The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis . Arthritis Rheum . 1992;35:498–502
  14. Bellamy N . Osteoarthritis clinical trials (candidate variables and clinimetric properties) . J Rheumatol . 1997;24:768–778
  15. Bellamy N , Buchanan WW , Goldsmith CH , et al.   Validation study of WOMAC (a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee) . J Rheumatol . 1988;15:1833–1840
  16. Merck Research Laboratories. Vioxx Gastrointestinal Outcomes Research Study. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf. Accessed July 22, 2004.
  17. Whitehead A , Whitehead J . A general parametric approach to meta-analysis of randomized clinical trials . Stat Med . 1991;10:1665–1677
  18. Mamdani M , Rochon PA , Juurlink DN , et al.   Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs . BMJ . 2002;325:624
  19. Weil J , Colin-Jones D , Langman M , et al.   Prophylactic aspirin and risk of peptic ulcer bleeding . BMJ . 1995;310:827–830
  20. McAdam BF , Catella-Lawson F , Mardini IA , et al.   Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2 (the human pharmacology of a selective inhibitor of COX-2) . Proc Natl Acad Sci USA . 1999;96:272–277 [published erratum appears in Proc Natl Acad Sci USA. 1999;96:5890]
  21. FitzGerald GA , Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med . 2001;345:433–442
  22. Bresalier RS , Sandler RS , Quan H , et al.  Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl J Med . 2005;352:1092–1102
  23. Ott E , Nussmeier NA , Duke PC , et al.   Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery . J Thorac Cardiovasc Surg . 2003;125:1481–1492
  24. Nussmeier NA , Whelton AA , Brown MT , et al.   Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery . N Engl J Med . 2005;352:1081–1091
  25. Baraf HSB, Fuentealba C, Greenwald M, et al. Gastrointestinal tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized, blinded clinical study (EDGE Trial). Poster presented at the American College of Rheumatology annual meeting, October 19, 2004.
  26. White WB , Faich G , Whelton A , et al.   Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac . Am J Cardiol . 2002;89:425–430
  27. White WB , Faich G , Borer JS , Makuch RW . Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib . Am J Cardiol . 2003;92:411–418
  28. Mamdani M , Rochon P , Juurlink DN , et al.   Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly . Arch Intern Med . 2003;163:481–486
  29. Campen DH , Graham D , Cheetam C , et al.   Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective-nonsteroidal anti-inflammatory drugs . [abstract 1756] Arthritis Rheum . 2004;50(suppl 9):S657
  30. Kimmel SE , Berlin JA , Reilly M , et al.   Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction . Ann Intern Med . 2005;142:157–164
  31. Ray WA , Stein CM , Daugherty JR , et al.   COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease . Lancet . 2002;360:1071–1073
  32. Solomon DH , Schneeweiss S , Glynn RJ , et al.   Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults . Circulation . 2004;109:2068–2073
  33. Solomon SD , McMurray JJ , Pfeffer MA , et al.  Adenoma Prevention with Celecoxib (APC) Study Investigators   Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention . N Engl J Med . 2005;352:1071–1080
  34. http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.pdf. Accessed January 12, 2005.
  35. http://www.fda.gov/cder/drug/InfoSheets/HCP/Naproxen-hcp.pdf. Accessed January 12, 2005.
  36. Chenevard R , Hurlimann D , Bechir M , et al.   Selective COX-2 inhibition improves endothelial function in coronary artery disease . Circulation . 2003;28:107; 405-409
  37. Walter MF , Jacob RF , Day CA , et al.   Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification (comparison to sulfonamide COX-2 inhibitors and NSAIDs) . Atherosclerosis . 2004;177:235–243
  38. Silverstein FE , Graham DY , Senior JR , et al.   Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs (A randomized, double-blind, placebo-controlled trial) . Ann Intern Med . 1995;123:241–249
  39. MacDonald TM , Morant SV , Robinson GC , et al.   Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure (cohort study) . BMJ . 1997;315:1333–1337
  40. Schaffer D , Marschner I , Eagle C , et al.   The effect of exposure duration on NSAID-related serious gastrointestinal adverse event rates . J Gastroentrol Hepatol . 2003;18(Suppl):B15

 This study was supported by a grant from Pharmacia Corporation and Pfizer, Inc. The study design as well as data analysis and interpretation were performed by the study design committee, of which the sponsor was a member. The study sponsors were responsible for data collection and management, in collaboration with the authors. Two independent Gastrointestinal Events adjudication committees performed the data analysis and interpretation of gastrointestinal events. The authors had full access to all the data and had final responsibility for data analysis, interpretation, manuscript preparation and the decision to submit for publication.Conflict of Interest Statement: Gurkirpal Singh received research support from Searle, Pharmacia, Pfizer, Merck, Boehringer Ingelheim, TAP Pharmaceuticals, Wyeth, Altana, Glaxo Smith Kline, Novartis, and Centocor; consultancies, travel grants, speakers bureau from Searle, Pharmacia, Pfizer, Merck and Boehringer Ingelheim. John G. Fort and Carl Wallmark were employees of Pharmacia/Pfizer and own stock in Pfizer, Inc. Jay L. Goldstein: consultancies, honoraria, travel grants, travel expenses, speakers bureau, and research grants from Searle, Pharmacia, Pfizer, TAP Pharmaceuticals, and Astra-Zeneca. Roger A. Levy: Investigator and Speakers bureau (Pfizer, Aventis, Wyeth and Schering-Plough); Advisory board (Pfizer and Novartis). Patrick S. Hanrahan: travel grants from Pfizer. Alfonso E. Bello: former employee of Pharmacia/Pfizer. Lilia Andrade-Ortega: Advisory board (Pfizer); travel grants (Schering Plough). Naurang M. Agrawal: honoraria (Pharmacia and Pfizer); advisory board (Pfizer). Glenn M. Eisen: consultancies and honoraria (Pfizer). William F. Stenson: consultancies (Pharmacia and Pfizer). George Triadafilopoulos: research support from Pfizer, Astra-Zeneca and TAP Pharmaceuticals; consultant to Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth; honoraria and travel support for lectures and meetings from Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth.

PII: S0002-9343(05)00913-7

doi: 10.1016/j.amjmed.2005.09.054

The American Journal of Medicine
Volume 119, Issue 3 , Pages 255-266 , March 2006

Article Tools

* Image Usage & Resolution